Ameriprise
STRO icon

Ameriprise’s Sutro Biopharma STRO Stock Holding History

Ameriprise’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-18,040
Closed -$332K – 4146
2024
Q4 		$332K Sell
18,040
-183
-1% -$5.59K ﹤0.01% 3686
2024
Q3 		$631K Buy
18,223
+83
+0.5% +$3.25K ﹤0.01% 3405
2024
Q2 		$532K Buy
18,140
+3,239
+22% +$128K ﹤0.01% 3395
2024
Q1 		$842K Buy
14,901
+1,777
+14% +$78.5K ﹤0.01% 3237
2023
Q4 		$563K Buy
13,124
+2,566
+24% +$81.4K ﹤0.01% 3415
2023
Q3 		$366K Sell
10,558
-2,002
-16% -$87.2K ﹤0.01% 3520
2023
Q2 		$584K Sell
12,560
-402
-3% -$20K ﹤0.01% 3380
2023
Q1 		$599K Buy
12,962
+4,746
+58% +$301K ﹤0.01% 3356
2022
Q4 		$664K Sell
8,216
-39
-0.5% -$2.71K ﹤0.01% 3300
2022
Q3 		$457K Buy
+8,255
New +$489K ﹤0.01% 3428

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Ameriprise's STRO Position: Q1 2025 in Review

Ameriprise sold out of Sutro Biopharma (STRO) in Q1 2025, closing a stake of 18,040 shares — an estimated $332K sold.

Ameriprise first reported a position in STRO in Q3 2022 and held it in 10 quarters. The position peaked at $842K in Q1 2024. 112 funds tracked by Wall St. Rank hold STRO as of Q1 2025.

  • Ameriprise reported no remaining Sutro Biopharma position as of Q1 2025 after selling out during the quarter.
  • Ameriprise sold 18,040 Sutro Biopharma shares in Q1 2025, an estimated $332K.
  • Ameriprise first reported a position in Sutro Biopharma in Q3 2022 and held it in 10 quarters.
  • Ameriprise's Sutro Biopharma position peaked at $842K in Q1 2024.
  • 112 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2025.

Based on Ameriprise's 13F filing for Q1 2025, filed 14 May 2025.